Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 6 | Diabetology & Metabolic Syndrome

Fig. 6

From: Methionine sulfoxide reductase B2 protects against cardiac complications in diabetes mellitus

Fig. 6

ROS induced methionine sulfoxidation (MetO) in human diabetic hearts. A. Western blot analysis of MetO in normal (NH #1–3) and diabetic human heart tissue(DH #1–6). GAPDH served as a loading control. B. Quantification of MetO signal intensity. C. Western blot analysis of methionine sulfoxide reductase A and B2 (MsrA and B2) in normal (NH #1–3) and diabetic heart tissue (DH #1–6). GAPDH served as loading a loading control. D. Quantification of MsrA and MsrB2 signal intensity. E. Western blot analysis of LC3l/II and p62 in normal (NH #1–3) and diabetic heart tissue (DH #1–6). GAPDH served as a loading control. F. Quantification of LC3l/II and p62 signal intensity. G. Western blot analysis of DRP1 and OPA1 in normal (NH #1–3) and diabetic heart tissues (DH #1–6). GAPDH served as a loading control. H. Quantification of MetO intensity

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us